Johnson & Johnson Reports Lower Mortality Rates in Impella-Supported High-Risk Coronary Procedures

Johnson & Johnson (NYSE:JNJ) has presented findings from three clinical analyses indicating lower mortality rates among patients undergoing high-risk percutaneous coronary intervention (HRPCI) with Impella heart pump support compared with mortality figures reported in the CHIP-BCIS3 study.

The findings were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and included real-world and observational registry data involving 1,379 patients treated at hospitals across the United States and Europe.

The analyses examined mortality outcomes following Impella-supported coronary interventions, with results reported at different intervals ranging from hospital discharge to 180 days after treatment.

Although the findings suggest potentially favourable outcomes, the analyses were observational and do not establish that Impella support caused the differences in mortality rates.

European Registry Reports 6.1% Mortality at 30 Days

The first analysis examined outcomes among 279 patients who underwent elective Impella-supported HRPCI at hospitals in Germany, Switzerland and Austria.

Researchers reported an all-cause mortality rate of 6.1% at 30 days following the procedure.

At 180 days, the all-cause mortality rate was 7.9%.

The analysis provides information about patient outcomes following planned high-risk coronary interventions supported by the Impella heart pump.

However, because the findings were derived from observational data, they cannot independently determine whether Impella support improved survival compared with alternative treatment strategies.

US Registry Shows 3.4% Cardiovascular Mortality at Hospital Discharge

A second analysis evaluated 522 patients included in a multicentre US registry.

Among patients receiving Impella support during HRPCI, cardiovascular mortality was 3.4% at hospital discharge.

Kaplan-Meier estimates indicated cardiovascular mortality rates of 4.7% at 30 days and 6.5% at 90 days.

These results were compared with findings from the CHIP-BCIS3 study, which reported approximately 8% cardiovascular mortality among patients treated with Impella by day four following randomisation.

The registry findings showed numerically lower mortality rates than those reported in CHIP-BCIS3.

However, differences in patient characteristics, study design, follow-up periods and outcome measurement mean the figures should not be interpreted as a direct comparison of treatment effectiveness.

PROTECT III Analysis Identifies Lower In-Hospital Mortality

The third analysis used data from the PROTECT III study to examine patients meeting the eligibility criteria established for CHIP-BCIS3.

Researchers identified 578 patients who satisfied those criteria.

Within this group, the reported in-hospital all-cause mortality rate was 4.7%.

This compared with an approximately 8% cardiovascular mortality figure reported in CHIP-BCIS3.

The findings provide additional observational evidence regarding outcomes among patients receiving Impella support during high-risk coronary procedures.

Nevertheless, the two figures measure different mortality endpoints and were obtained from separate study populations.

As a result, the numerical difference does not demonstrate that Impella support provides a survival advantage over another treatment approach.

Impella Clinical Evidence Remains Under Evaluation

Johnson & Johnson presented the three analyses as part of its continuing assessment of Impella heart pump support in patients undergoing complex coronary interventions.

The combined datasets included 1,379 patients across European and US hospitals, providing information about outcomes in different clinical settings.

High-risk percutaneous coronary intervention involves procedures performed in patients with complex coronary artery disease or other clinical characteristics that can increase procedural risk.

Impella devices provide temporary mechanical circulatory support during certain cardiac procedures.

The latest analyses contribute to the available clinical evidence, although their observational nature limits the conclusions that can be drawn about treatment-related mortality benefits.

The company also disclosed that physicians Matthias Bossard and Vasileios Panoulas, who were quoted in its announcement, are paid consultants for Johnson & Johnson MedTech.

PROTECT IV Randomised Trial Results Expected in 2027

Johnson & Johnson confirmed that its PROTECT IV randomised controlled trial remains ongoing, with results expected in 2027.

The study is intended to provide further evidence regarding the clinical use of Impella support in high-risk coronary interventions.

Randomised controlled trials are particularly important when evaluating treatment effectiveness because they are designed to reduce selection bias and other factors that can influence comparisons between patient groups.

The forthcoming PROTECT IV findings could therefore provide additional context for interpreting the observational results presented at TCT.

Until those results become available, the latest registry analyses should be regarded as supportive clinical observations rather than definitive evidence of a mortality benefit.

Johnson & Johnson Impella Outlook Focuses on Further Clinical Validation

The three analyses presented by Johnson & Johnson reported mortality outcomes ranging from 3.4% cardiovascular mortality at hospital discharge in the US registry to 7.9% all-cause mortality at 180 days in the European cohort.

The PROTECT III subgroup analysis also reported in-hospital all-cause mortality of 4.7% among patients meeting CHIP-BCIS3 eligibility criteria.

Although these figures were numerically below the approximately 8% cardiovascular mortality reported in CHIP-BCIS3, differences in endpoints, follow-up periods and study populations prevent definitive conclusions about comparative effectiveness.

The findings add to the body of observational evidence concerning Impella-supported HRPCI, while the ongoing PROTECT IV randomised trial represents an important next stage in evaluating clinical outcomes.

Investors and healthcare professionals will be monitoring the expected 2027 results for further evidence regarding the device’s role in high-risk coronary interventions.

Johnson & Johnson stock price